18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer
NCT ID: NCT02701699
Last Updated: 2024-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2014-12-31
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, a radiotracer called Fluoroazomycin Arabinoside (FAZA) will be used to measure hypoxia in the patient's tumour. FAZA has already been used in many cancers including lung cancer. Patients who consent to participate in this trial will receive 1 FAZA PET Scan prior to their first radiotherapy treatment
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer
NCT01542177
Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy
NCT00765986
Cervix Hypoxia FAZA
NCT01549730
A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA
NCT00756691
FAZA PET/MRI Pancreas
NCT04395469
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18-F-FAZA Scan
All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
18-F-FAZA
All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18-F-FAZA
All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with stage II or III lung cancer (both NSCLC and SCLC) qualifying for radiotherapy to the primary tumor, with or without treatment of mediastinal or hilar lymph nodes
3. Intention to treat using radiotherapy according to the current treatment policies of the PMH Lung Group
4. Concurrent systemic therapy allowed
5. A negative serum pregnancy test within the two week interval immediately prior to PET-CT imaging, in women of child-bearing age
6. Ability to provide written informed consent to participate in the study
Exclusion Criteria
2. Previous systemic therapy
3. Active malignancy other than lung cancer
4. Unable to remain supine for more than 60 minutes
5. Pregnancy
6. Age less than 18 years old
7. Failure to provide written informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alex Sun, MD
Role: PRINCIPAL_INVESTIGATOR
The Princess Margaret Cancer Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHN REB 13-6528-C
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.